Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Preparation and evaluation of technetium-99m labeled albumin particles for glioma tumor imaging in rat

Document Type : Research Paper

Authors

A. Mikaeili
Zh. Fallah
M. Goudarzi
M. Erfani

Radiation Application Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-3486, Tehran - Iran

https://doi.org/10.24200/nst.2024.1596
Abstract
Albumin particles are used in nuclear medicine as carriers of diagnostic and therapeutic radionuclides. Temperature was used to prepare these particles. After size determination, the particles were marked with gamma-irradiated radionuclide 99mTc in the presence of stannous chloride as a reducing agent. Chromatography methods analyzed radiochemical purity. For labeled particles, stability in normal saline and biodistribution in normal and glioma tumorized rats were investigated. The size of particles was determined below 50 nm. Radiochemical purity of more than 98% was obtained. Evaluation of labeled particle stability showed radiochemical purity of more than 90% during 6 hr in saline and human serum solutions. Biodistribution studies revealed liver and tumor uptake followed by high kidney washout. Gamma imaging scintigraphy in rats showed tumors and kidneys. The results confirmed the ability of marked particles as a tumor diagnostic radiopharmaceutical.

Highlights

  1. Rempel S.A, Ge S, Gutiérrez J.A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res. 1999;5:237.

 

  1. Hirose M, Tachibana A, Tanabe T. Recombinant human serum albumin hydrogel as a novel drug delivery vehicle. Mat Sci Eng. 2010;30:664.

 

  1. Elzoghby A.O, Samy W.M, Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control Release. 2012;157:168.

 

  1. Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol. Asp. Med. 2012;33:209.

 

  1. Abeyrathne E.D, Lee H.Y, Ahn D.U. Egg white proteins and their potential use in food processing or as nutraceutical and pharmaceutical agents. Poult. Sci. 2013;92:3292.

 

  1. Verma D, Gulati N, Kaul S, Mukherjee S, Nagaich U. Protein based nanostructures for drug delivery. J. Pharm (Cairo). 2018;16:9285854.

 

  1. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release. 2008;132:171.

 

  1. Elzoghby A.O, Samy W.M, Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release. 2012;157:168.

 

  1. Kratz F. A clinical update of using albumin as a drug vehicle-a commentary. J. Control Release. 2014;190:331.

 

  1. Lomis N, Westfall S, Farahdel L, Malhotra M, Shum-Tim D, Prakash S. Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterial. 2016;6:116.

 

  1. Patel J.J, Alzahrani T. Myocardial Perfusion Scan. (StatPearls Publishing; Treasure Island (FL)). 2022.

 

  1. Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J. Labelled Comp Radiopharm. 2017;60:502.

 

  1. Mikaeili A, Erfani M, Sabzevari O. Synthesis and evaluation of a 99mTc-labeled chemokine receptor antagonist peptide for imaging of chemokine receptor expressing tumors. Nucl. Med. Biol. 2017;54:10.

 

  1. Green C.H. Technetium-99m production issues in the United Kingdom. J. Med. Phys. 2012;37:66.

 

  1. Kornyei J, Ozker K. Technetium-99m radiopharmaceuticals: manufacture of kits. IAEA technical report series no 466. Vienna: International Atomic Energy Agency. 2008;108-111.

 

  1. Papachristou M, Priftakis D, Xanthopoulos S, Datseris I, Bouziotis P. Biodistribution of intravenous [99mTc]Tc-phytate in mouse models of chemically and foreign-body induced sterile inflammation. Am. J. Nucl. Med. Mol. Imaging. 2022;12:91.

Keywords

Albumin
Particles
Technetium-99m
Tumor
Imaging
  1. Rempel S.A, Ge S, Gutiérrez J.A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res. 1999;5:237.

 

  1. Hirose M, Tachibana A, Tanabe T. Recombinant human serum albumin hydrogel as a novel drug delivery vehicle. Mat Sci Eng. 2010;30:664.

 

  1. Elzoghby A.O, Samy W.M, Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control Release. 2012;157:168.

 

  1. Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: From bench to bedside. Mol. Asp. Med. 2012;33:209.

 

  1. Abeyrathne E.D, Lee H.Y, Ahn D.U. Egg white proteins and their potential use in food processing or as nutraceutical and pharmaceutical agents. Poult. Sci. 2013;92:3292.

 

  1. Verma D, Gulati N, Kaul S, Mukherjee S, Nagaich U. Protein based nanostructures for drug delivery. J. Pharm (Cairo). 2018;16:9285854.

 

  1. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release. 2008;132:171.

 

  1. Elzoghby A.O, Samy W.M, Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release. 2012;157:168.

 

  1. Kratz F. A clinical update of using albumin as a drug vehicle-a commentary. J. Control Release. 2014;190:331.

 

  1. Lomis N, Westfall S, Farahdel L, Malhotra M, Shum-Tim D, Prakash S. Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterial. 2016;6:116.

 

  1. Patel J.J, Alzahrani T. Myocardial Perfusion Scan. (StatPearls Publishing; Treasure Island (FL)). 2022.

 

  1. Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J. Labelled Comp Radiopharm. 2017;60:502.

 

  1. Mikaeili A, Erfani M, Sabzevari O. Synthesis and evaluation of a 99mTc-labeled chemokine receptor antagonist peptide for imaging of chemokine receptor expressing tumors. Nucl. Med. Biol. 2017;54:10.

 

  1. Green C.H. Technetium-99m production issues in the United Kingdom. J. Med. Phys. 2012;37:66.

 

  1. Kornyei J, Ozker K. Technetium-99m radiopharmaceuticals: manufacture of kits. IAEA technical report series no 466. Vienna: International Atomic Energy Agency. 2008;108-111.

 

  1. Papachristou M, Priftakis D, Xanthopoulos S, Datseris I, Bouziotis P. Biodistribution of intravenous [99mTc]Tc-phytate in mouse models of chemically and foreign-body induced sterile inflammation. Am. J. Nucl. Med. Mol. Imaging. 2022;12:91.

Home